Indeed, HBB mRNA level in primary tumour samples is generally low (0–0.9%), while increased expression is detected in 7 out of 19 metastatic prostate tumours (6.3–18.1%) (P=0.042) (Fig. 5b; Supplementary Fig. 9). The gene discussed is HBB; the disease is prostate neoplasm.